Showing results (1-10 of 297) with videos related to
Sort By:
Pageof 30
Nature Reviews. Drug Discovery|May 19, 2026
Realizing the potential of agonistic antibody immunotherapyMark S Cragg, Xiaojie Yu, Christopher Paluch, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 4, 2017
Improving Antibody-Based Cancer Therapeutics Through Glycan EngineeringXiaojie Yu, Michael J E Marshall, Mark S Cragg, et al.Cell Biology International|October 16, 2007
Cancer: a matter of life cycle?Jekaterina Erenpreisa, Mark S CraggCancer Cell International|September 13, 2013
Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewalJekaterina Erenpreisa, Mark S CraggMolecular & Cellular Oncology|June 17, 2016
Death by a thousand knives: Multiple BH3-only proteins are required for maximal apoptosis triggered through the BCRMatthew J Carter, Mark S CraggEuropean Journal of Immunology|February 3, 2015
Rehabilitation or the death penalty: autoimmune B cells in the dockLekh N Dahal, Mark S CraggBlood|October 11, 2003
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagentsMark S Cragg, Martin J GlennieOncoimmunology|April 9, 2016
Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapyAli Roghanian, Mark S Cragg, Björn FrendéusNature Immunology|July 6, 2023
Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapyFalk Nimmerjahn, Gestur Vidarsson, Mark S CraggFrontiers in Immunology|May 14, 2023
Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectivesOsman Dadas, Ayse Ertay, Mark S CraggPageof 30